SV7 Impact Medicine Fund LP's Form 4 filing
Xilio Therapeutics, Inc.XLO · filed Oct 28, 2021
- Accession no.
- 0000899243-21-041838
- Filed
- Oct 28, 2021, 12:55 PM ET
- Trade date
- Oct 26, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions and 4 derivative transactions. It was filed 2 days after the trade.
This filing was later replaced by the amendment 0000899243-21-042710 (Nov 3, 2021). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| SV7 Impact Medicine Fund LPCIK 0001780602 | 10% Owner |
| SV7 (Imf) GP LLPCIK 0001889859 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 26, 2021 | Common Stock | CConversionAcquired | +998,544 | –F1 | – | 998,544 | Direct | |
| Oct 26, 2021 | Common Stock | CConversionAcquired | +998,544 | –F1 | – | 998,544 | Indirect | |
| Oct 26, 2021 | Common Stock | CConversionAcquired | +302,588 | –F1 | – | 1,301,132 | Direct | |
| Oct 26, 2021 | Common Stock | CConversionAcquired | +302,588 | –F1 | – | 1,301,132 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 26, 2021 | Common Stock | CConversionDisposed | −998,544 | $0.00 | $0 | 0 | Direct | |
| Oct 26, 2021 | Common Stock | CConversionDisposed | −998,544 | $0.00 | $0 | 0 | Indirect | |
| Oct 26, 2021 | Common Stock | CConversionDisposed | −302,588 | $0.00 | $0 | 0 | Direct | |
| Oct 26, 2021 | Common Stock | CConversionDisposed | −302,588 | $0.00 | $0 | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date.
Referenced by the price of 4 transactions in Table I.